DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)

74
Time for baby talk!
Chat to one of Fertility Associates’ fertility
experts at Stand 12 and be in to win an iPad!
And while you’re there, pick up your free
copies of our “Little Details” magazine, our
mini Biological Clock and our preconception
pregnancy wheel. They are great resources
to pass on to your patients.
The Cetaphil range provides gentle yet effective
cleansing and moisturising for all skin types and is
ideal for sensitive, infant and compromised skin.
The Gentle Skin Cleanser can be used with or without
water, is fragrance free and is proven to be one of the
gentlest non-soap cleansers 1 .
When it comes to fertility, we understand.
www.fertilityassociates.co.nz
FAL 031
Available in pharmacies, supermarkets & Farmers stores. www.cetaphil.co.nz
Always read the label. Use only as directed. ® Trademark Galderma. For more information call Galderma
on: 0800 174 104 (New Zealand). Reference 1: Galderma Data on File.
VESICARE is
fully funded 1
Come to CSL Biotherapies stand 76-77
to find out more about VESICARE and be in to
WIN an Adscope TM 657 valued at over $400.
Fully funded for patients with a documented
intolerance to oxybutynin.
FULLY FUNDED
Special authority applies. 1
REFERENCES: 1. PHARMAC funding criteria.
VESICARE ® is fully funded under special authority from 1 January 2010. NAME OF MEDICINE: VESICARE ® contains 5 or 10 mg of solifenacin succinate in a film-coated tablet. INDICATION: VESICARE ® is indicated for
the treatment of unstable bladder with symptoms of increased urinary urgency, frequent micturition, and/or urge incontinence. DOSAGE: In adults, the recommended dose is 5mg once daily. If needed, this can be
increased to 10mg once daily. Tablets should be swallowed whole. Not recommended for use in children. CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients, Urinary retention,
Uncontrolled narrow angle glaucoma, Myasthenia gravis, Severe gastro-intestinal condition (including toxic megacolon), Patients undergoing hemodialysis, Patients with severe hepatic impairment, Patients with
severe renal impairment or moderate hepatic impairment and on treatment with a strong CYP3A4 inhibitor. WARNINGS AND PRECAUTIONS: Other causes of frequent urination (heart failure or renal disease) should be
assessed before treatment with VESICARE ® . If urinary tract infection is present, an appropriate antibacterial therapy should be started, Clinically significant bladder outflow obstruction at risk of urinary retention,
Gastrointestinal obstructive disorders, Risk of decreased gastrointestinal motility, Severe renal impairment (doses should not exceed 5 mg for these patients), Moderate hepatic impairment (Child-Pugh score of 7
to 9)( (doses should not exceed 5 mg for these patients), Concomitant use of a strong CYP3A4 inhibitor (doses should not exceed 5 mg for these patients), Pregnancy, Lactation, and may effect ability to drive and
use machines. ADVERSE EFFECTS: Dry mouth, Constipation, Nausea, Dyspepsia, Abdominal pain, Blurred vision, Urinary tract infection, Somnolence, Dysgeusia, Dry eyes, Fatigue, Oedema, Difficulty in micturition,
Faecal impaction, Colonic obstruction, Urinary retention, Gastro-oesophageal reflux diseases, Dry throat, Vomiting, Cystitis, Dizziness, Headache, Nasal dryness, Dry skin, Pruritus, Rash, Urticaria, and Hallucinations.
INTERACTIONS: anticholinergics, metoclopramide, cisapride, ketoconazole, CYP3A4 inhibitors, verapamil, diltiazem, CYP3A4 inducers, rifampicin, phenytoin, carbamazepin. MEDICINE CLASSIFICATION: Prescription
Medicine. Please review the full data sheet before prescribing VESICARE ® . Full data sheet is available from CSL Biotherapies (NZ) Ltd, PO Box 62 590, Greenlane, Auckland 1546, www.csl.co.nz, or the Medsafe
website www.medsafe.govt.nz Based on VESICARE ® data sheet dated September 2008. VESICARE ® is a registered trademark of Astellas Pharma International. VESI-079-04/11 DA1111PG